Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation

Phase 2, randomised, open-label trial of Molecular hydrogen in Atrial fibrillation (AFib) (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Composite primary endpoint: absence of early arrhythmia recurrence and improvement in quality of life at 3 months. Planned start Feb 2026; status: authorised.